The current data indicate that MSC represent a promising alternative strategy and encouraging results in the treatment of Crohn's disease, Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis. PubMed, Clin Rev Allergy Immunol. 2013 Jan 8. (Also see: Lupus Treatments and Scleroderma Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.